On the basis of our previous data showing that simultaneous KAT2A/KAT2B loss reduced neuroblastoma viability, we hypothesized that the KAT2A/KAT2B PROTAC, GSK-699, may be a pharmacologic intervention for MYCN-amplified neuroblastoma. The gene discussed is KAT2A; the disease is neuroblastoma.